Lapin Immune Features of Experimental Escherichia Coli-Pseudomonas Aeruginosa Combined Bacterin: A Research Account
Abstract
The study aims to develop prototype candidate bacterins, monotypic and combined [balanced x-x and unbalanced 2x-x] from the gram-negative uropathogenic E. coli and P. aeruginosa. These bacterins were applied for specific immune priming of rabbits using multisite injection protocols in weekly dosing for two weeks followed by a week leave, then bled in homologous prime-boost schedules. The secondary immune responses were tempted. The tripartite arms of the immune responses were investigated as TNF alpha, bone marrow mitotic index, splenic body index, IL17 cytokine, antibody titers, cytokine IL4, IL2, and IL10. Combined bacterins are known to exhibit immune interference phenomena. The phenomenology of immune interference in bacterin combinations appeared as follows: one enhances the other, one dampens the other, and one does not affect the other. E. coli was found to be of major and minor immune interfering potentials depending on the nature of bacterin combinations in the sense of quantitative ratios of the bacterin units per unit volume of the developed biologics. Both immune-enhancing and immune-inhibiting forms of immune interference were noted. The developed urocombined bacterin seems to be a novel contribution in continuum with the licensed Uromune, Urovac, and Uro-Vaxom bacterin.
Keywords: bacterin, biologics, combination, development, dampening, interference.
Full Text:
PDFReferences
SHNAWA I. Letters in Immunobiology of Bacterin. Germany, Lap Lambert Academic Publishing, 2018.
SKIBINSKI D, BAUNDER B, SINGH M, et al. Combination vaccines. Journal of Global Infectious Diseases, 2011, 3(1): 63-72.
JATANA S.K. & NAIR M.N.G. Combination vaccines. Medical Journal of Armed Force Institute, 2007, 63: 167-171.
LARZABAL M., CATALDI A.A. & VILTE D.A. Human and Veterinary Vaccines against Pathogenic Escherichia coli. In ERJAVEC M.S. (Ed.) The Universe of Escherichia coli. IntechOpen, 2019, 1-10.
MEHDIE M.S. The Role of Secretory Immunity in Pyuria Patients. MSC Thesis] Babylon/Iraq: University of Babylon, 2000.
ABDULWAHID I.M.-S. & AL-HARMOOSH, R.A.H. Reciprocal intermolecular antigenic competition between E. coli and P. aeruginosa. Al-Qadisiah Medical Journal, 2020, 9(15): 154-164.
SHNAWA I.M.S., ABD F.A. & HASSEN A.H. Laboratory Development Cellular Immune Features and Immune Interference of Prototype Escherichia Coli and Pseudomonas Aeruginosa Combined Bacterins in A Lapin Model. Vaccine Research and Vaccination, 2020, 6(2): Article ID 014.
CARROLL K., MILLER S., MORSE S.A., & MIETZNER T.A. Jawetz Melnick & Adelbergs Medical Microbiology, 27th ed. New York. McGraw-Hill Education/Medical, 2015, 153-177.
LEVINSON W., CHIN-HONG P., JOYCE E.A., & NUSSBAUM B. Review of Medical Microbiology and Immunology, 15th ed. New York. McGraw-Hill/Lange, 2018, 26-83.
BANKER D.D. Modern Practice in Immunization. Bombay, Popular Prakashan.1980, 185-206
BLACK D.D. Microbiology, 7th ed. Asia John Wiley Sons Inc., 2008, 1-8.
PLOTKIN S. History of vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2017, 111: 12283-12287.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Understanding Vaccines. NIH Publication No. 03-4219, 2003, 20-24.
CARROLL S. Vaccine evaluation process needs urgent reform. Pharmaceutical Journal, 2014, 293(7833): Online.20066896
SCHAUT R.G.M., BOGGIATTO P.M., PALMER M., et al. Mucosal cellular immune responses following Escherichia coli O157:H7 bacterin vaccination associated with reduced fecal shedding. Journal of Immunology, 2018, 200(1 supplement)59, 22.
TOMITA G.M., RAY C., NICKERSON S.C., et al. A comparison of two commercially available Escherichia coli J5 vaccines against intra-mammary challenge. Journal of Dairy Science, 2000, 83: 2276-2281.
MAYERS L.L. Vaccination of cows with an Escherichia coli bacterin for the prevention of naturally occurring diarrheal disease in their calves. American Journal of Veterinary Research, 1976, 37(7): 531-534.
MAURER J. Production of cross-protective autogenous bacterin vaccine strains for controlling Escherichia coli infection in Poultry. Project No.3698, University of Georgia, Athens, Ga, 2018.
LI L., THOFNER J., CHRISTENSEN J.P., et al. Evaluation of the efficacy of an autogenous Escherichia coli vaccine in broiler breeders. Avian Pathology.2017;45(1): 300-308.
LOREZO-GOMEZ M.F., PADILLA-FERNANDEZ B., GARCIA-CAIADDO F. et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus treatment with antibiotics. International Urogynecology, 2013, 24: 127-134.
UEHLING D.T., HOPKINS W.J., BEIERLE L.M. et al. Vaginal mucosal vaccination for recurrent urinary tract infection. Extended Phase II clinical trial. The Journal of Infectious Diseases, 2001, 183: 81-83.
WAGENLENHNER F.M.E., BALLARINI S., PILATZ A. et al. A randomized double blind parallel group, multi-centric clinical study of Escherichia coli lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urologia International, 2015, 95: 167-176.
HOGGARTH A., WEAVER A., PU Q. et al. Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa. Drug Design, Development and Therapy, 2019; 13: 909-924.
PRIEBE G.P. Mechanism of adaptive immunity to P. Aeruginosa in the lung. National Institute of Health. Project#3R01HL092515-01A2512009-2012.
WU W., HAUNG J., DUAN B. et al. TH17 stimulating protein vaccine confer protection against Pseudomonas aeruginosa pneumonia. American Journal of Respiratory and Critical Care Medicine, 2012, 186: 420-427.
RYU J.I., WUI S.R., KO A. et al. Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System. Journal Microbiology Biotechnology, 2017, 27(6): 1539-1548.
ZAIDI T.S., PRIEBE G.P., & PIER G.B. Zaidi, T. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infection and Immunity, 2006, 74(2): 975-983.
LYNCH J.A. Successful bacterin therapy in a case of chronic Staphylococcal infection. Canadian Veterinary Journal, 1983, 63(1): 1-5.
Cell Regeneration Therapy. Personalized immunotherapy of cancer. Autogenous bacterin. 2017.
NAUTS H.C. The Beneficial Effects of Bacterial Infections on Host Resistance to Cancer and Results of 440 cases. Cancer Research Institute Monograph No. 8;1980; NY 10028
MARCOVE R.C., SOUTHAM C.M., LEVIN A. et al. A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five. Surgical Forum, 1971, 22: 434–435.
KUMAR R., CHANDRA R., SHUKLA S.K. et al. Hydropericardium syndrome (HPS) in India: a preliminary study on the causative agent and control of the disease by inactivated autogenous vaccine. Tropical Animal Health Production, 1997, 29(3): 158-184.
MOUAHID M., BOUZOUBAA K. & ZOUAGUI Z. Preparation and use of autogenous bacterin against infectious coryza in chicken. Veterinary Research Communication, 1991, 15(6): 413-419.
CHOKEPHAIBULKIT K. (2002) Combination vaccines. Journal of the Medical Association of Thailand, 2002, 85 Suppl 2: 694–699.
WILDE D.M. Combination vaccines: how and why? Lessons learned. Global Vaccine and Immunization Research Forum, 2016.
DECKER M.D & EDWARDS K.M. Combination vaccines: problems and promise. The Journal of Pediatrics, 2000, 137(3): 291-295.
WARD J.I. Strategies for development of combination vaccines. The Pediatric Infectious Disease Journal, 2001, 20(11 Suppl.): 5-9.
SHENDE P. & WAGHCHAURE M. Combination vaccines for prophylaxis of infectious conditions. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47(1): 695-704.
BALL L.K., FALK L.A., HORNE A.D., & FINN T.M. Evaluating the immune response to combination vaccines. Clinical Infectious Diseases, 2001, 33(Suppl.4): 299-305.
EMEA. Requirement for combined veterinary vaccine. Committee for Veterinary Medicinal Products, CVMP/IWP/52/97-Final; 2000, 1-6.
DAOUD, A., DIAB, R., ABOUL SAOUD, S. et al. Preparation and evaluation of combined inactivated vaccine containing rota, corona viruses, Escherichia coli bacterin and Clostridium perfringens type Ctoxoid (Entero-4). Journal of Veterinary Medical Research, 2005, 15(2): 232-237.
LARAY G.P. New discoveries in calf vaccination strategies: Finding the pearls in research. Animal Sciences. North Dakota State University, 2012; PPT.
STOLTENOW C., CORTESE V.S., SEEGER J.T., et al. Immunologic responses of beef calves to concurrent application (intranasal and systemic administration) and systematically administered Mannheimia haemolytica bacterin-leukotoxoid. The Bovine Practitioner, 2011, 45(2): 132-138.
CORTESE V.S., SEEGER J.T., STOKKA G.S.et al. Serologic response to Mannheimia haemolytica in calves concurrently inoculated with inactivated or modified-live preparations of M. haemolytica and viral combination vaccines containing modified-live bovine herpesvirus type 1. American Journal of Veterinary Research, 2011, 72(11): 1541-1549.
DAGAN R., POOLMAN J., & SIEGRIST C.A. Glycoconjugate vaccines and immune interference: A review. Vaccines, 2010, 28(34): 5513-5523.
KONINI A. Simulating immune interference on the effect of bivalent glycoconjugate vaccine against Haemophilus influenzae serotype “a” and “b”. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 5: 1-8.
AMEND D.F. & JOHNSON K.A. Evidence for lack of antigenic competition among various combinations of Vibrio anguillarum, Yersinia ruckeri, Aeromonas salmonicida and Renibacterium salmoninarum bacterin when administered to salmonid fishes. Journal of Fish Diseases, 1984, 7(4): 293-299.
FINDLOW H. & BORROW R. Interaction of conjugate vaccines and co-administered vaccine. Human Vaccines and Immunotherpeutics, 2016, 12(1): 226-230.
TAUSSIG M.J., MOZES E., SHEARER G.M., & SELA M. Studies on the mechanism of antigenic competition: analysis of competition between synthetic peptide antigens. European Journal of Immunology, 1972, 2: 448-452.
SINGH B.R., CHANDRA M., AGRAWAL R., & NAGRAJAN B. Antigenic competition among different “O” antigens of Salmonella enterica sup-species enterica serovars during hyperimmunization in pony mares. Indian Journal of Experimental Biology, 2006, 44: 1022-1025.
RAADSMA H.W., O MERA T.J., LEHRBACH P.R., & SCHWARTZKOFF V. Protective antibody titers and antigenic competition in multivalent Dichelobacter nodosus fimbrial vaccines using characterized rDNA antigens. Veterinary Immunology and Immunopathology 1994, 40(3): 253-274.
SHNAWA I.M.S. & MHEDIE M.S. Mucosal agglutinating antibodies to antigens of bacterin associated with urinary tract infection in adults. Kufa Medical Journal, 2004, 7(1): 237-244.
SHNAWA I.M.S. & ABD F.G. Nature of IL17 cytokine response in rabbits prime-boost with Escherichia coli-Pseudomonas aeruginosa prototype bacterin combinations. Medico-Legal Update, 2020, 20: 1054-1059.
Refbacks
- There are currently no refbacks.
